These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 14555310

  • 1. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
    Reichardt VL, Milazzo C, Brugger W, Einsele H, Kanz L, Brossart P.
    Haematologica; 2003 Oct; 88(10):1139-49. PubMed ID: 14555310
    [Abstract] [Full Text] [Related]

  • 2. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
    Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, Massaia M, D'Addio A, Giudice V, Di Bello C, Cavo M, Conte R, Gugliotta G, Baccarani M, Lemoli RM.
    Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
    Röllig C, Schmidt C, Bornhäuser M, Ehninger G, Schmitz M, Auffermann-Gretzinger S.
    J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.
    Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF.
    J Clin Oncol; 2006 Jul 01; 24(19):3107-12. PubMed ID: 16754937
    [Abstract] [Full Text] [Related]

  • 9. [In vitro anti-tumor effect of CTL induced by HSP70-Id complex-modified dendritic cells].
    Wang ZH, Ye Q, Hu ZQ, Ye ZQ, Yu X, Shen GX.
    Zhonghua Zhong Liu Za Zhi; 2006 Jul 01; 28(7):481-5. PubMed ID: 17147108
    [Abstract] [Full Text] [Related]

  • 10. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
    Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, Voena C, Bianchi A, Coscia M, Besostri B, Peola S, Stiefel T, Even J, Novero D, Boccadoro M, Pileri A.
    Blood; 1999 Jul 15; 94(2):673-83. PubMed ID: 10397734
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
    Yi Q, Szmania S, Freeman J, Qian J, Rosen NA, Viswamitra S, Cottler-Fox M, Barlogie B, Tricot G, van Rhee F.
    Br J Haematol; 2010 Sep 15; 150(5):554-64. PubMed ID: 20618329
    [Abstract] [Full Text] [Related]

  • 13. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
    Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B, Carsten C, Diehl V, Bohlen H.
    Br J Haematol; 2000 Mar 15; 108(4):805-16. PubMed ID: 10792287
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
    Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, Rajapaksa R, Engleman EG, Blume KG, Levy R.
    Biol Blood Marrow Transplant; 2000 Mar 15; 6(6):621-7. PubMed ID: 11128812
    [Abstract] [Full Text] [Related]

  • 17. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
    de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ.
    Clin Cancer Res; 2003 Nov 01; 9(14):5091-100. PubMed ID: 14613986
    [Abstract] [Full Text] [Related]

  • 18. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
    Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mulé JJ.
    Cancer Res; 2001 Dec 01; 61(23):8513-9. PubMed ID: 11731436
    [Abstract] [Full Text] [Related]

  • 19. [Induction of active antitumor immune response by myeloma idiotype protein-pulsed dendritic cells].
    Yin XR, Zhang M, Luo YY, Lin X, He PC, Chen LM, Cai RB, Guo GL.
    Ai Zheng; 2005 Jun 01; 24(6):657-62. PubMed ID: 15946473
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.